A thyroxine-containing peptide can induce murine experimental autoimmune thyroiditis by unknown
Brief  De~n/U've Report 
A  Thyroxine-containing  Peptide  Can  Induce  Murine 
Experimental  Autoimmune  Thyroiditis 
By Patricia R. Hutchings,* Anne Cooke,$ Kim Dawe,* 
Brian g.  Champion,~ Mario Geysen, II Robert Valerio,  II 
and Ivan M.  Roitt* 
From the *Immunology Department, University College and Middlesex Medical School, London 
WIP 9PG, United Kingdom; the tlmmunology Department, Glaxo Inc., Research Triangle 
Park, North Carolina 27709; the $Pathology Department, University of Cambridge, Cambridge 
CB2 IQP, United Kingdom; and IIChiron Mimotopes Pty. Ltd., Clayton, Victoria 3168, 
Australia 
Summal"y 
A synthetic peptide based on a sequence containing thyroxine at position 2553 in thyroglobulin 
(Tg), and already shown to be recognized by two clonotypically distinct murine Tg autoreactive 
T cell hybridomas, can trigger primed lymph node cells to transfer thyroiditis to naive recipients. 
Donor lymph node cells could be prepared from mice immunized either with intact mouse Tg 
or with this peptide itself. After a second exposure to the priming antigen in vitro, both these 
populations induced 100% thyroiditis in recipient animals. The importance of the T4 residue 
in the development of disease was demonstrated by the failure of Tg tryptic peptides depleted 
of T4 to stimulate pathogenic effectors in vitro, even when the lymph node cells had been taken 
from mice primed with whole Tg. We conclude that this T4-containing 12mer sequence is a 
major thyroiditogenic epitope in CBA/J mice although we cannot exclude the possibility that 
there are other pathogenic epitopes present in the whole Tg molecule. 
E 
xperimental autoimmune thyroiditis (EAT) is character- 
ized by an inflammatory infiltrate of the thyroid gland. 
It has been shown that the cells comprising this infiltrate 
include macrophages and T  cells, and in animal models of 
induced thyroiditis, the disease has been shown to be T cell 
dependent (1). 
Thyroglobulin (Tg) a 660-kD glycoprotein, is synthesized 
in the thyroid by follicular epithelial cells, and tyrosine residues 
within the molecule are iodinated by thyroid peroxidase to 
produce the thyroid hormones tri-iodothyronine (T3) and 
thyroxine (T4). In human Tg, T3 and T4 residues may be 
formed from tyrosines at positions 5, 2553, 2567, and 2746. 
There is evidence from animal models that the iodine con- 
tent of Tg may influence its autoantigenicity (2, 3), and EAT 
induced in  mice is  much less  severe if poorly iodinated 
Tg is used for immunization (4). Similarly, human studies 
have shown that raised dietary iodine correlates with an in- 
crease in the incidence and severity of autoimmune thyroid 
lesions (5). 
In previous studies (6) using synthetic T4-containing pep- 
tides, we showed that two donotypically distinct murine Tg 
autoreactive T  cell hybridomas recognized an epitope con- 
taining T4 at position 2553 in human Tg. Sets of overlap- 
ping 5mer to 12met peptides around this T4 showed that 
the most potent peptide was a 9mer beginning at Asp 2551, 
and replacement of the T4 with any of the 20 naturally oc- 
curring amino acids led to loss of antigenicity. Since the parent 
T  cell lines of the hybridomas have been shown to induce 
thyroiditis on adoptive transfer, the T4-containing sequence 
appeared to be implicated as a pathogenic epitope in murine 
EAT. To confirm the pathogenic potential of this sequence, 
we have used the T4-containing 12mer to induce thyroiditis 
in vivo, and the results of these studies are the subject of this 
communication. 
Materials and Methods 
Preparation of  Antigens, Mice, and Immunization Protocol.  Mouse 
thyroglobulin (MTg) was prepared by extraction from pooled 
homogenized thyroids (Parkes outbred strain reared in our own 
laboratory) as previously  described (7). CBA/J mice, 6-8 wk old, 
of either sex (NIMR, London, UK), were immunized either in 
the base of the tail with 50/~g MTg emulsified  in CFA (MTg/CFA; 
H37Ra; Difco Laboratories, Detroit, MI) or with 50/~g MTg in 
PBS intravenously followed 3 h later by an intravenous injection 
of 20 #g LPS (MTg/LPS: Salmonella enteridites; Sigma Chemical 
Co., St. Louis, MO).  Mice were boosted 7 d later with 25/~g 
MTg/CFA in both hind footpads or 50 #g MTg/LPS as previously. 
Preparation of Tg Peptides.  Peptides  lacking thyroxine (T4-) 
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peptide  Ac-STDD(T4)ASFSRAbNH2,  hereafter  referred to  as 
the T4(2553) peptide, was produced on a synthesizer (9050; Mil- 
ligen/Biosearch, Burlington, MA) also as described  previously (10). 
Transfer of  Thyroiditis.  The  popliteal  lymph  nodes  from 
MTg/CFA-immunized mice or spleens  from MTg/LPS-immunized 
mice were taken on day 16 and cultured for 72 h in petri dishes 
or flasks at 5  x  l&/ml in R.PMI 1640 (Gibco, Paisley, Scotland) 
with 5% FCS and other supplements, as described previously (6), 
together with MTg (40 ~g/ml) or peptide (2.5 or 5 ~g/ml) to acti- 
vate and expand effector T cells. After washing, 2  x  107 viable 
lymph node cells or 3-5  x  107 spleen cells were injected intrave- 
nously into normal syngeneic recipients and their thyroids exam- 
ined 14 d later. 
Evaluation of Thyroid Infiltration.  Thyroids were fixed in 4% 
phosphate-buffered formalin and sections stained with H and E. 
For each mouse, there are 12 possible scores (two lobes at six levels). 
0, no infiltration; 1, any definite infiltration up to 20%; 2, between 
20 and 50% infiltration; 3, between 50 and 75% infiltration; 4, 
gland totally infiltrated but follicles still discernible. The score for 
each mouse is the total divided by the number of observations (as 
occasionally, one lobe may be missing on some sections). The av- 
erage thyroiditis for each group is the mean  _+  SE of all of the 
mice in the group. 
Proliferation Assay.  Mice were immunized  once in both hind 
footpads with 50 #g MTg/CFA. The popliteal lymph nodes were 
excised 8 d later and cultured  for 72 h in 96-well plates in sup- 
plemented RPMI 1640 at 5  x  lOVwell with the antigens indi- 
cated. Proliferative responses were assessed  by the overnight incor- 
poration  of mI-deoxyuridine  and results expressed as the mean 
cpm  _+  SEM of triplicate cultures. 
Results and Discussion 
Thyroiditis may be induced in high responder strains of 
mice by injecting Tg with a suitable adjuvant, usually CFA 
(11) or LPS (12), and in some studies, Bordetella pertussis has 
been used to augment the response (13). In our hands, thy- 
roid lesions could be demonstrated in CBA/J mice on day 
28 after the injection of 50/~g MTg/CFA in the base of the 
tail on day 0 and into the hind footpads on day 7. Equally 
effective was the injection of 50 #g MTg followed 3 h later 
by 20/xg LPS both administered intravenously and repeated 
on day 7. 
In many reports, thyroiditis can be induced by adoptive 
transfer of spleen or draining lymph nodes from mice im- 
munized with Tg and adjuvants (14-17), and we found that 
adoptive transfer produced better thyroiditis than in situ im- 
munization. Draining lymph nodes or spleens taken 16 d after 
the first priming dose from animals immunized with MTg/ 
CFA or MTg/LPS, respectively, were cultured in vitro for 
3 d with antigen as described in Materials and Methods, be- 
fore transfer to normal syngeneic recipients. Thyroids were 
examined 14 d later when lesions were nearly always observed 
as  shown in Table  1,  Exps.  3,  4,  and 6. 
We confirmed the observations of other groups (14,  17) 
Table  1.  Transfer of Thyroiditis by T4 (2553) Peptide or MTg-primed Lymphocytes Reactivated In Vitro 
In vitro  Highest score 
Immunization  Stimulation  Cells injected  (day 14)  Average 
thyroiditis 
Exp.  Antigen  Amount  Antigen  Amount  Cell  Amount  No. of mice  0  1  2  3  4  Incidence  _+SEM 
/~g  /zg/rnl 
1  MTg/CFA  50  pep  2.5  Lymph node  2  ￿  10  7  4  2*  2  4/4  1.69  _+  0.27 
2  pep/CFA  5  pep  2.5  3  3  3/3  0.59  _+  0.17 
3  MTg/CFA  50  MTg  40  3  1  2  2/3  0.63  _+  0.31 
pep  5  3  3  3/3  2.3  +  0.1 
pep/CFA  20  MTg  40  2  2  0/2  0.04 
pep  5  3  3  3/3  2.73  _+  0.13 
4  MTg/CFA  50  MTg  40  3  2  1  3/3  1.8  _+  0.61 
pep/CFA  20  MTg  40  2  2  0/2  0 
pep  5  3  1  2  3/3  2.14  +_  0.33 
5  pep/LPS  20  MTg  40  Spleen  4  x  107  3  1  2  2/3  0.98  +  0.5 
pep  5  3  3  3/3  3.25  _+  0.4 
6  MTg/CFA  50  MTg  40  Lymph node  2  x  107  4  2  2  4/4  1.7  +  0.075 
PPD  25  4  4  0/4  0.09  +_  0.02 
T4-free 
tryptic 
peptide  2.5  3  3  0/3  0.02  _+  0.03 
* Number of animals with that grade of thryoiditis in one or more sections. 
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tide in vitro Popliteal  lymph node cells  from mice immunized in the footpad 
8 d previously with MTg/CFA were stimulated  for 72 h in vitro with 
MTg or peptide. Proliferative responses were assessed by the overnight in- 
corporation  of mI-deoxyuridine  radiolabel and results e~pressed as mean 
cpm  _+SE. 
that in vitro activation with Tg antigens is essential for the 
transfer of thyroiditis to naive recipients (see Table 1, Exp. 
6). Lymph node cells prepared from mice immunized with 
MTg/CFA 8 d earlier could be induced to proliferate by both 
MTg and the T4 (2553) peptide (Ac-STDD[T4]ASFSRAL- 
NH2) (Fig.  1). This clearly shows that T cells recognizing 
the T4(2553)  epitope,  previously defined only by clonal T 
cell populations (6), are well represented in MTg-primed lymph 
node populations.  To explore whether these T  cells could 
elicit thyroiditis,  the T4(2553) peptide was used to activate 
lymph node cells before transfer. MTg-primed lymph node 
cells cultured with T4(2553)  peptide induced unequivocal 
thyroid lesions in all recipients examined (Table 1, Exp.  1). 
In further experiments,  mice were immunized with 5-20 
#g T4(2553)  peptide and either CFA or LPS as adjuvant. 
Lymph nodes or spleen were taken as before and activated 
for 72 h with peptide (2.5 or 5 #g/ml) before transfer. Every 
recipient of these cells had developed thyroid lesions by day 
14 (Table 1, Exps. 2-5). These experiments show conclusively 
that the T4(2553) peptide itself can act as a thyroiditogenic 
epitope, since neither donor nor recipient was primed or chal- 
lenged with whole Tg in an immunogenic form. Further- 
more, the ability of the peptide to stimulate T but not rele- 
vant B cells (as judged by the absence of anti-MTg antibodies 
in the recipient) provides added confirmation of the impor- 
tance of T  cells as pathogenic mediators  of the thyroiditis 
lesion. 
In spite of repeated attempts to induce thyroiditis in situ 
with T4(2553)  peptide and CFA or LPS at  doses ranging 
from 1 to 25/zg, no convincing thyroid lesions have been 
seen. Furthermore,  although draining lymph nodes  from 
T4(2553) peptide/CFA-immunized animals could be stimu- 
lated in vitro with peptide to transfer excellent thyroiditis 
(as shown already in Table 1), stimulation of these same cells 
in vitro with MTg failed to produce any lesions in recipient 
animals (Table 1, Exps. 3 and 4).  However, in one experi- 
ment, spleen cells from mice immunized with peptide and 
LPS, rather than CFA as adjuvant,  did transfer thyroiditis 
(although there were fewer lesions) after activation in vitro 
with MTg (Table 1, Exp. 5). The reasons for these data are 
not clear at present.  Experiments are in progress  to inves- 
tigate whether the choice of adjuvant affects the T cell subsets 
stimulated and whether LPS augments antigen presentation 
by triggered B cells, since it is quite possible that the concen- 
tration in vitro of the relevant peptide after processing of MTg 
by cells from T4(2553)/CFA-treated  animals may not reach 
the threshold for effector activation (David Wraith, personal 
communication). Although it has been shown that the pres- 
ence of B cells is not obligatory for the development of thy- 
roiditis (18), they may well augment responses to certain de- 
terminants by more efficient presentation  (19). 
The ability of the T4(2553) peptide to induce thyroiditis 
under appropriate experimental conditions accords well with 
our previous studies on the importance of iodination for the 
activity of Tg in this system. However, our inability to date 
to induce thyroiditis directly by immunization with T4(2553) 
peptide/CFA in situ (under circumstances where MTg itself 
is  effective) raises the  possibility  that  other  thyroxine- 
containing epitopes may be of pathogenic importance.  The 
failure of Tg tryptic peptides depleted of T4 to boost MTg 
immunized cells in vitro (Table 1, Exp. 6) provides a further 
argument against the view that noniodinated epitopes play 
a role in the disease model although in fairness, it  should 
be noted that the peptides were derived from human Tg and 
one cannot exclude the possibility that the noniodinated epi- 
topes do not crossreact adequately with those derived from 
the mouse protein. 
We are indebted to Drs. P. G. H. Byfield  and C. T. J. Chan for preparing and providing the T4-free 
tryptic human Tg peptides. 
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